Myriad Opens Tumor BRACAnalysis CDx Lab in Europe

CDx Lab in Europe

Myriad Genetics announced today that it has established a European laboratory that will offer its Tumor BRACAnalysis CDx test to guide treatment with PARP inhibitors, namely AstraZeneca’s olaparib.

Three-Person IVF

Three-person in vitro fertilization is on the way in the UK, and should be ready for use in preventing the birth of children with mitochondrial disease around two years, says a panel tasked with examining the state of this science.

The goal of these procedures is to help women who have mitochondrial diseases have healthy babies.

Courtagen Initiates Partnership with Sciencewerke for International Distribution of Clinical Next Generation Sequencing Tests for Neurological and Metabolic Disorders

Sciencewerke to Provide Courtagen’s Clinical Testing to Clinicians in Singapore, Malaysia, and Indonesia

WOBURN, MA. May 29, 2014 – Courtagen Life Sciences, Inc., an innovative molecular information company, announced today an international distribution agreement with Sciencewerke Pte Ltd. Sciencewerke is headquartered in Singapore, and has offices in Malaysia and Indonesia. The company anticipates this partnership will serve as a model for similar commercial relationships with leading distributors in markets around the world.

Personalis Launches the ACE Clinical Exome™

Personalis introduces the first test to combine an enhanced clinical exome with genome-wide structural variant detection.

Menlo Park, CA – Personalis, Inc., the leading provider of advanced medical exome and genome sequencing and interpretation services today announced the launch of an early access program to the Personalis ACE Clinical Exome™, a single test that integrates enhanced exome sequencing with genome-wide structural variant detection to increase diagnostic yield. “Personalis’ goal is to improve diagnostic yield while decreasing overall cost and turnaround time compared with traditional serial genetic testing. Until now separate testing has been required for exome-wide small variant detection and genome-wide structural variant detection” said Personalis’ CEO John West “Our ACE Clinical Exome replaces this serial genetic testing approach with a single, convenient test”.